Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Collegium Pharma (NQ: COLL )

39.21 -0.49 (-1.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 739,358
Open 39.86
Bid (Size) 39.17 (6)
Ask (Size) 39.21 (2)
Prev. Close 39.70
Today's Range 38.73 - 40.51
52wk Range 20.95 - 40.95
Shares Outstanding 32,213,751
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
The Analyst Landscape: 4 Takes On Collegium Pharmaceutical
Via Benzinga

Performance

YTD
+25.55%
+25.55%
1 Month
+4.78%
+4.78%
3 Month
+22.38%
+22.38%
6 Month
+2.11%
+2.11%
1 Year
+72.28%
+72.28%

More News

Read More
Collegium Completes Acquisition of Ironshore Therapeutics
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Via Investor's Business Daily
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts
Via Benzinga
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Organon Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
Via Investor's Business Daily
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Collegium Reports Second Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
Via Benzinga
In a market where value is scarce, NASDAQ:COLL offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
NASDAQ:COLL is an undervalued gem with solid fundamentals.
Via Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
Via Investor's Business Daily
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium to Participate in Jefferies Global Healthcare Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces $35 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Collegium Reports First Quarter 2024 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Collegium Announces CEO Transition
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.